<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">36594004</PMID><DateRevised><Year>2023</Year><Month>03</Month><Day>01</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">1226-8453</ISSN><JournalIssue CitedMedium="Print"><Volume>47</Volume><Issue>2</Issue><PubDate><Year>2023</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Journal of ginseng research</Title><ISOAbbreviation>J Ginseng Res</ISOAbbreviation></Journal><ArticleTitle>COVID-19 infection and ginseng: Predictive influenza virus strains and non-predictive COVID-19 vaccine strains.</ArticleTitle><Pagination><StartPage>347</StartPage><EndPage>348</EndPage><MedlinePgn>347-348</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jgr.2022.12.007</ELocationID><Abstract><AbstractText>Vaccines help protect people from infections. However, Coronavirus 2019 (COVID-19) vaccinees often still become infected with COVID-19 variants (breakthrough infections) and may go on to suffer from long COVID symptoms due to short-lasting immunity and less-effective protection provided by available vaccines. Moreover, the current COVID-19 vaccines do not prevent viral transmission and ward off only about 15% of breakthrough infections. To prepare more effective vaccines, it is essential to predict the viral strains that will be circulating based on available epidemiological data. The World Health Organization recommends in advance which influenza strains are expected to be prevalent during influenza season to guide the production of influenza vaccines by pharmaceutical companies. However, future emerging COVID-19 strain(s) have not been possible to predict since no sound epidemiological information has been established. Thus, for more effective protection, immune stimulators alone or in combination with vaccines would be preferable to protect people from COVID-19 infection. One of those remedies would be ginseng, which has been used for potentiating immunity in the past.</AbstractText><CopyrightInformation>&#xa9; 2022 The Korean Society of Ginseng. Publishing services by Elsevier B.V.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rhee</LastName><ForeName>Dong-Kwon</ForeName><Initials>DK</Initials><AffiliationInfo><Affiliation>School of Pharmacy, Sungkyunkwan University, Suwon, Republic of Korea.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016421">Editorial</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>12</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>Korea (South)</Country><MedlineTA>J Ginseng Res</MedlineTA><NlmUniqueID>100890690</NlmUniqueID><ISSNLinking>1226-8453</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">BTI, Breakthrough infection</Keyword><Keyword MajorTopicYN="N">Covid-19</Keyword><Keyword MajorTopicYN="N">Korean ginseng</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2 COVID-19, Severe acute respiratory syndrome coronavirus-2</Keyword><Keyword MajorTopicYN="N">antiviral</Keyword><Keyword MajorTopicYN="N">influenza virus</Keyword><Keyword MajorTopicYN="N">vaccine</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>8</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>12</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>4</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>3</Day><Hour>1</Hour><Minute>58</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>12</Month><Day>29</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36594004</ArticleId><ArticleId IdType="pmc">PMC9797409</ArticleId><ArticleId IdType="doi">10.1016/j.jgr.2022.12.007</ArticleId><ArticleId IdType="pii">S1226-8453(22)00178-6</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Collier A.Y., Yu J., McMahan K., Liu J., Chandrashekar A., Maron J.S., Atyeo C., Martinez D.R., Ansel J.L., Aguayo R., et al. Differential kinetics of immune responses elicited by covid-19 vaccines. N Engl J Med. 2021 Nov 18;385(21):2010&#x2013;2012.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8531985</ArticleId><ArticleId IdType="pubmed">34648703</ArticleId></ArticleIdList></Reference><Reference><Citation>Suryawanshi R.K., Chen I.P., Ma T., Syed A.M., Brazer N., Saldhi P., Simoneau C.R., Ciling A., Khalid M.M., Sreekumar B., et al. Limited cross-variant immunity from SARS-CoV-2 Omicron without vaccination. Nature. 2022 Jul;607(7918):351&#x2013;355.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9279157</ArticleId><ArticleId IdType="pubmed">35584773</ArticleId></ArticleIdList></Reference><Reference><Citation>Dejnirattisai W., Huo J., Zhou D., Zahradn&#xed;k J., Supasa P., Liu C., Duyvesteyn H.M.E., Ginn H.M., Mentzer A.J., Tuekprakhon A., et al. SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses. Cell. 2022 Feb 3;185(3):467&#x2013;484. e15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8723827</ArticleId><ArticleId IdType="pubmed">35081335</ArticleId></ArticleIdList></Reference><Reference><Citation>Mannar D., Saville J.W., Zhu X., Srivastava S.S., Berezuk A.M., Tuttle K.S., Marquez A.C., Sekirov I., Subramaniam S. SARS-CoV-2 Omicron variant: antibody evasion and cryo-EM structure of spike protein-ACE2 complex. Science. 2022 Feb 18;375(6582):760&#x2013;764.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9799367</ArticleId><ArticleId IdType="pubmed">35050643</ArticleId></ArticleIdList></Reference><Reference><Citation>VanBlargan L.A., Errico J.M., Halfmann P.J., Zost S.J., Crowe J.E., Jr., Purcell L.A., Kawaoka Y., Corti D., Fremont D.H., Diamond M.S. An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies. Nat Med. 2022 Mar;28(3):490&#x2013;495.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8767531</ArticleId><ArticleId IdType="pubmed">35046573</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao Y., Wang J., Jian F., Xiao T., Song W., Yisimayi A., Huang W., Li Q., Wang P., An R., et al. Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies. Nature. 2022 Feb;602(7898):657&#x2013;663.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8866119</ArticleId><ArticleId IdType="pubmed">35016194</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoffmann M., Kr&#xfc;ger N., Schulz S., Cossmann A., Rocha C., Kempf A., Nehlmeier I., Graichen L., Moldenhauer A.S., Winkler M.S., et al. The Omicron variant is highly resistant against antibody-mediated neutralization: implications for control of the COVID-19 pandemic. Cell. 2022 Feb 3;185(3):447&#x2013;456. e11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8702401</ArticleId><ArticleId IdType="pubmed">35026151</ArticleId></ArticleIdList></Reference><Reference><Citation>Planas D., Saunders N., Maes P., Guivel-Benhassine F., Planchais C., Buchrieser J., Bolland W.H., Porrot F., Staropoli I., Lemoine F., et al. Considerable escape of SARS-CoV-2 Omicron to antibody neutralization. Nature. 2022 Feb;602(7898):671&#x2013;675.</Citation><ArticleIdList><ArticleId IdType="pubmed">35016199</ArticleId></ArticleIdList></Reference><Reference><Citation>Soraci L., Lattanzio F., Soraci G., Gambuzza M.E., Pulvirenti C., Cozza A., Corsonello A., Luciani F., Rezza G. COVID-19 vaccines: current and future perspectives. Vaccines (Basel) 2022 Apr 13;10(4):608.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9025326</ArticleId><ArticleId IdType="pubmed">35455357</ArticleId></ArticleIdList></Reference><Reference><Citation>Feikin D.R., Higdon M.M., Abu-Raddad L.J., Andrews N., Araos R., Goldberg Y., Groome M.J., Huppert A., O'Brien K.L., Smith P.G., et al. Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression. Lancet. 2022 Mar 5;399(10328):924&#x2013;944.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8863502</ArticleId><ArticleId IdType="pubmed">35202601</ArticleId></ArticleIdList></Reference><Reference><Citation>van Doremalen N., Purushotham J.N., Schulz J.E., Holbrook M.G., Bushmaker T., Carmody A., Port J.R., Yinda C.K., Okumura A., Saturday G., et al. Intranasal ChAdOx1 nCoV-19/AZD1222 vaccination reduces viral shedding after SARS-CoV-2 D614G challenge in preclinical models. Sci Transl Med. 2021;13(607) Aug 18 eabh0755.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9267380</ArticleId><ArticleId IdType="pubmed">34315826</ArticleId></ArticleIdList></Reference><Reference><Citation>Lund F.E., Randall T.D. Scent of a vaccine. Science. 2021 Jul 23;373(6553):397&#x2013;399.</Citation><ArticleIdList><ArticleId IdType="pubmed">34437109</ArticleId></ArticleIdList></Reference><Reference><Citation>Vora S.M., Lieberman J., Wu H. Inflammasome activation at the crux of severe COVID-19. Nat Rev Immunol. 2021 Nov;21(11):694&#x2013;703.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8351223</ArticleId><ArticleId IdType="pubmed">34373622</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Aly Z., Bowe B., Xie Y. Long COVID after breakthrough SARS-CoV-2 infection. Nat Med. 2022 Jul;28(7):1461&#x2013;1467.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9307472</ArticleId><ArticleId IdType="pubmed">35614233</ArticleId></ArticleIdList></Reference><Reference><Citation>Callaway E. Fast-evolving COVID variants complicate vaccine updates. Nature. 2022 Jul;607(7917):18&#x2013;19.</Citation><ArticleIdList><ArticleId IdType="pubmed">35760853</ArticleId></ArticleIdList></Reference><Reference><Citation>Seo S.H. Ginseng protects ACE2-transgenic mice from SARS-CoV-2 infection. Front Biosci (Landmark Ed) 2022 Jun 6;27(6):180.</Citation><ArticleIdList><ArticleId IdType="pubmed">35748256</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>